JP2022521410A5 - - Google Patents

Info

Publication number
JP2022521410A5
JP2022521410A5 JP2021549435A JP2021549435A JP2022521410A5 JP 2022521410 A5 JP2022521410 A5 JP 2022521410A5 JP 2021549435 A JP2021549435 A JP 2021549435A JP 2021549435 A JP2021549435 A JP 2021549435A JP 2022521410 A5 JP2022521410 A5 JP 2022521410A5
Authority
JP
Japan
Prior art keywords
antigens
vaccine composition
composition according
antigen
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021549435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521410A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/019367 external-priority patent/WO2020172635A1/en
Publication of JP2022521410A publication Critical patent/JP2022521410A/ja
Publication of JP2022521410A5 publication Critical patent/JP2022521410A5/ja
Priority to JP2025056539A priority Critical patent/JP2025098224A/ja
Pending legal-status Critical Current

Links

JP2021549435A 2019-02-21 2020-02-21 最適化されたワクチン組成物およびその製造方法 Pending JP2022521410A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025056539A JP2025098224A (ja) 2019-02-21 2025-03-28 最適化されたワクチン組成物およびその製造方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962808760P 2019-02-21 2019-02-21
US62/808,760 2019-02-21
US201962817902P 2019-03-13 2019-03-13
US62/817,902 2019-03-13
PCT/US2020/019367 WO2020172635A1 (en) 2019-02-21 2020-02-21 Optimized vaccine compositions and methods for making the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025056539A Division JP2025098224A (ja) 2019-02-21 2025-03-28 最適化されたワクチン組成物およびその製造方法

Publications (2)

Publication Number Publication Date
JP2022521410A JP2022521410A (ja) 2022-04-07
JP2022521410A5 true JP2022521410A5 (https=) 2023-09-07

Family

ID=72145134

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021549435A Pending JP2022521410A (ja) 2019-02-21 2020-02-21 最適化されたワクチン組成物およびその製造方法
JP2025056539A Pending JP2025098224A (ja) 2019-02-21 2025-03-28 最適化されたワクチン組成物およびその製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025056539A Pending JP2025098224A (ja) 2019-02-21 2025-03-28 最適化されたワクチン組成物およびその製造方法

Country Status (5)

Country Link
US (1) US20220088175A1 (https=)
EP (2) EP4729125A2 (https=)
JP (2) JP2022521410A (https=)
CN (1) CN113747915A (https=)
WO (1) WO2020172635A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116217714B (zh) * 2022-10-14 2024-03-15 华中农业大学 一种全猪源pedv单克隆抗体及其抗原表位
WO2024102923A1 (en) * 2022-11-09 2024-05-16 Centivax, Inc. Low dose vaccine compositions
WO2024220936A1 (en) * 2023-04-20 2024-10-24 Centivax, Inc. Vaccine compositions and uses thereof
CN119219767B (zh) * 2023-06-29 2025-05-27 华中农业大学 两株全猪源pedv单克隆中和抗体及其用途
WO2025235418A1 (en) * 2024-05-05 2025-11-13 National Health Research Institutes Virus-like particle, preparation method thereof, and use thereof in preparing vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE520708T1 (de) * 2003-03-28 2011-09-15 Us Gov Health & Human Serv Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung
WO2008054540A2 (en) * 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
US10059746B2 (en) * 2011-04-04 2018-08-28 University Of Iowa Research Foundation Methods of improving vaccine immunogenicity
AU2012271336B2 (en) * 2011-06-17 2017-03-02 University Of Tennessee Research Foundation Group A streptococcus multivalent vaccine
EP3937179A1 (en) * 2012-05-21 2022-01-12 Distributed Bio Inc Epitope focusing by variable effective antigen surface concentration
US10736956B2 (en) * 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
EP3307311A4 (en) * 2015-06-15 2019-02-13 Emory University MULTIVALENT ENTOVIRUS VACCINE COMPOSITIONS AND RELATED USES
WO2018073340A1 (en) * 2016-10-19 2018-04-26 Redbiotec Ag Influenza virus vaccine
CA3040337A1 (en) * 2016-10-26 2018-05-03 Curevac Ag Lipid nanoparticle mrna vaccines

Similar Documents

Publication Publication Date Title
JP2022521410A5 (https=)
JP2019526580A5 (https=)
Young et al. Virus-like particles: designing an effective AIDS vaccine
RU2407749C2 (ru) Иммуногенная композиция и способ разработки вакцины, основанной на слитом белке
Van Ginkel et al. Vaccines for mucosal immunity to combat emerging infectious diseases
JP2009539965A5 (https=)
Bramwell et al. The rational design of vaccines
JP2010516763A5 (https=)
JP2008534467A5 (https=)
JP2022172244A5 (https=)
JP2009516529A5 (https=)
JP2017515508A5 (https=)
Rezaei et al. Recent advances on HIV DNA vaccines development: Stepwise improvements to clinical trials
US20040047882A1 (en) Adjuvant for vaccines
WO2023024609A1 (zh) 一种新型冠状病毒疫苗的佐剂及其应用和新型冠状病毒二价重组疫苗
JP2006504644A5 (https=)
Wi et al. Protective immunity against nervous necrosis virus in convict grouper Epinephelus septemfasciatus following vaccination with virus-like particles produced in yeast Saccharomyces cerevisiae
US6641816B1 (en) Use of poxviruses as enhancer of specific immunity
JP2022514759A5 (https=)
JP2006512413A5 (https=)
JP2009501901A5 (https=)
Omoniyi et al. Designing a multi-epitope vaccine against the Lassa virus through reverse vaccinology, subtractive proteomics, and immunoinformatics approaches
JP2024520730A5 (https=)
Schneider-Ohrum et al. Virus-like particles for antigen delivery at mucosal surfaces
JP2008500963A5 (https=)